MIRA Pharmaceuticals (NASDAQ:MIRA) Rating Lowered to Sell at Wall Street Zen

MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.Get MIRA Pharmaceuticals alerts:Separately, Weiss Ratings restated a "sell (e+)" rating on shares of MIRA Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of "Sell".Read Our Latest Stock Report on MIRAMIRA Pharmaceuticals Price PerformanceMIRA stock opened at $1.39 on Friday. The stock has a market capitalization of $58.21 million, a price-to-earnings ratio of -0.91 and a beta of 1.72. The company has a 50-day moving average of $1.42 and a two-hundred day moving average of $1.40. MIRA Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $2.45. MIRA Pharmaceuticals (NASDAQ:MIRA - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($1.07). Equities analysts expect that MIRA Pharmaceuticals will post -0.6 EPS for the current fiscal year. Institutional Inflows and OutflowsLarge investors have recently modified their holdings of the company. International Assets Investment Management LLC acquired a new stake in MIRA Pharmaceuticals during the second quarter worth $42,000. Two Sigma Investments LP lifted its holdings in shares of MIRA Pharmaceuticals by 129.8% during the 3rd quarter. Two Sigma Investments LP now owns 45,703 shares of the company's stock worth $62,000 after acquiring an additional 25,816 shares during the period. XTX Topco Ltd acquired a new stake in shares of MIRA Pharmaceuticals during the 2nd quarter valued at about $26,000. Creative Planning bought a new stake in MIRA Pharmaceuticals in the second quarter valued at about $27,000. Finally, First American Bank raised its position in MIRA Pharmaceuticals by 150.0% in the third quarter. First American Bank now owns 50,000 shares of the company's stock worth $68,000 after purchasing an additional 30,000 shares in the last quarter. 35.16% of the stock is currently owned by institutional investors and hedge funds. About MIRA Pharmaceuticals (Get Free Report)MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.Featured StoriesFive stocks we like better than MIRA PharmaceuticalsHow to Evaluate a Stock Before Buying A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech MovesHow to trade using analyst ratings12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming3 Grocery Stocks That Can Help Take a Bite Out of Inflation Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in MIRA Pharmaceuticals Right Now?Before you consider MIRA Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MIRA Pharmaceuticals wasn't on the list.While MIRA Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here